相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Gefitinib Versus Pemetrexed as Second-Line Treatment in Patients With Nonsmall Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy (KCSG-LU08-01)
Jong-Mu Sun et al.
CANCER (2012)
Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
Victoria M. Rimkunas et al.
CLINICAL CANCER RESEARCH (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations
Teresa Moran et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non-Small-Cell Lung Cancer
Hua Bai et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer
Kang-Yi Su et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
Heae Surng Park et al.
LUNG CANCER (2012)
Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients
Aya Tanaka et al.
LUNG CANCER (2012)
Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation
June Koo Lee et al.
LUNG CANCER (2012)
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
King Pan Ng et al.
NATURE MEDICINE (2012)
Integrative genomics viewer
James T. Robinson et al.
NATURE BIOTECHNOLOGY (2011)
Extensive genomic and transcriptional diversity identified through massively parallel DNA and RNA sequencing of eighteen Korean individuals
Young Seok Ju et al.
NATURE GENETICS (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
Anthony C. Faber et al.
CANCER DISCOVERY (2011)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases
Sara E. Monaco et al.
HUMAN PATHOLOGY (2010)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer
Masayuki Takeda et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
Heounjeong Go et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Understanding resistance to EGFR inhibitors-impact on future treatment strategies
Deric L. Wheeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2009)
PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L. Sos et al.
CANCER RESEARCH (2009)
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2009)
Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
Sarah Park et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Alterations of the Notch pathway in lung cancer
Britta Westhoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (vol 103, pg 14907, 2006)
Junya Kuroda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
Junya Kuroda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
Michio Inukai et al.
CANCER RESEARCH (2006)
NOTCH1 mutations in T-cell acute lymphoblastic leukemia:: Prognostic significance and implication in multifactorial leukemogenesis
Yong-Mei Zhu et al.
CLINICAL CANCER RESEARCH (2006)
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
SW Han et al.
CLINICAL CANCER RESEARCH (2006)
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
GJ Riely et al.
CLINICAL CANCER RESEARCH (2006)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)